Targeted Phage Therapy for Alcoholic Hepatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Alcohol-related liver disease, particularly alcoholic hepatitis, lacks effective treatment options, with high mortality rates and limited understanding of specific pathogens contributing to its progression, despite intestinal dysbiosis and gut bacterial overgrowth being implicated.
Innovation Solution
Targeting specific virulence factor-expressing bacteria in the gut using bacteriophages that target E. coli expressing ecpR and/or kpsM genes, which are associated with mortality in patients with alcoholic hepatitis, as a therapeutic approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bacteriophage therapy is used to target specific virulence factor-expressing bacteria, then treatment effectiveness is improved, but device complexity increases
Solution Approach 1:
The patent segments the broad category of gut bacteria into specific subgroups based on virulence factor expression (ecpR and kpsM genes). Instead of treating all bacteria uniformly, the therapy targets only those E. coli strains that express specific virulence factors, dividing the treatment approach into precise, targeted components that address the root cause while sparing beneficial bacteria.
Solution Approach 2:
The patent applies local quality by using bacteriophages with specific host ranges that target only bacteria expressing particular virulence factors in specific locations (gut microbiota). The therapy is not uniformly applied to all bacteria but is localized to infect and lyse only the harmful virulence factor-positive strains, leaving other bacterial populations unaffected.
2Quantity of substance
If broad-spectrum antibiotics are used to treat gut bacterial overgrowth, then bacterial load is reduced, but harmful factors increase due to disruption of beneficial microbiota
Solution Approach 1:
The patent extracts and eliminates only the harmful component (virulence factor-expressing bacteria) from the gut microbiota system while leaving the beneficial components intact. Bacteriophages specifically infect and lyse E. coli strains carrying ecpR and/or kpsM genes, removing the pathogenic elements without disrupting the overall microbiota ecosystem or beneficial bacterial populations.
Solution Approach 2:
The patent converts the harmful presence of virulence factor-positive bacteria into a benefit by using these specific bacterial markers as targets for precision therapy. The virulence factors that cause harm become the very markers that guide the therapeutic action, allowing the therapy to selectively eliminate harmful bacteria while preserving beneficial ones, thus turning the problem of virulence factor expression into a solution for targeted treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of bacteriophages that target E. coli expressing ecpR and/or kpsM genes may improve outcomes for patients with alcohol-related liver disease by reducing bacterial virulence and potentially serving as a biomarker for disease severity and mortality, offering a novel therapeutic strategy.
Implementation Method 1
bacteriophage that target E. coli expressing ecpR and/or kpsM genes may be employed as a therapeutic, for instance, formulated as a medicament for the treatment of people with hepatitis or alcohol-related liver disease
Data Source
AI summary
Methods of diagnosing, monitoring progression or efficacy of therapy, and treating patients with hepatitis or other chronic liver diseases are provided.